Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dubermatinib (TP-0903) in FLT3-Mutated AML
NCT04518345Phase 1Completed
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dubermatinib in acute myeloid leukemia (AML). Primary endpoints: Maximum Tolerated Dose at 28 days, Composite Complete Response Rate at 5 years and 1 more. Started Nov 2020; status: completed.
02
Drugs
dubermatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04518345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518345.